Assembly Biosciences Inc (NASDAQ:ASMB) was the recipient of a large increase in short interest during the month of September. As of September 28th, there was short interest totalling 955,294 shares, an increase of 69.8% from the September 14th total of 562,467 shares. Based on an average trading volume of 259,433 shares, the days-to-cover ratio is presently 3.7 days. Approximately 4.2% of the shares of the company are sold short.
ASMB opened at $24.01 on Friday. The company has a market capitalization of $945.08 million, a P/E ratio of -9.90 and a beta of 0.80. Assembly Biosciences has a 12-month low of $23.05 and a 12-month high of $67.36.
Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.42). The business had revenue of $3.22 million during the quarter, compared to analysts’ expectations of $3.30 million. Assembly Biosciences had a negative return on equity of 66.34% and a negative net margin of 457.20%. As a group, analysts expect that Assembly Biosciences will post -4.12 EPS for the current year.
In other news, VP Uri A. Lopatin sold 15,204 shares of the firm’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $40.09, for a total transaction of $609,528.36. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Derek A. Small purchased 2,400 shares of the company’s stock in a transaction dated Thursday, July 19th. The shares were bought at an average cost of $41.48 per share, for a total transaction of $99,552.00. Following the acquisition, the chief executive officer now owns 668,091 shares in the company, valued at $27,712,414.68. The disclosure for this purchase can be found here. Company insiders own 18.20% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of ASMB. Schwab Charles Investment Management Inc. boosted its holdings in shares of Assembly Biosciences by 12.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 35,200 shares of the biopharmaceutical company’s stock worth $1,730,000 after buying an additional 3,800 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Assembly Biosciences by 1.3% in the first quarter. Northern Trust Corp now owns 223,000 shares of the biopharmaceutical company’s stock worth $10,958,000 after buying an additional 2,904 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Assembly Biosciences by 32.9% in the first quarter. New York State Common Retirement Fund now owns 19,940 shares of the biopharmaceutical company’s stock worth $980,000 after buying an additional 4,940 shares during the last quarter. Allianz Asset Management GmbH purchased a new position in shares of Assembly Biosciences in the first quarter worth approximately $2,130,000. Finally, Blair William & Co. IL boosted its holdings in shares of Assembly Biosciences by 87.1% in the first quarter. Blair William & Co. IL now owns 12,913 shares of the biopharmaceutical company’s stock worth $635,000 after buying an additional 6,013 shares during the last quarter. 65.21% of the stock is currently owned by institutional investors.
A number of brokerages have recently issued reports on ASMB. BidaskClub downgraded shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, July 13th. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday. Robert W. Baird began coverage on shares of Assembly Biosciences in a report on Wednesday, August 8th. They set an “outperform” rating and a $74.00 price target on the stock. ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 3rd. Finally, B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 price target on the stock in a report on Monday, October 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. Assembly Biosciences presently has a consensus rating of “Hold” and a consensus target price of $62.60.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Further Reading: Marijuana Stocks
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.